

Tjerk Sj Opstal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8930398/publications.pdf>

Version: 2024-02-01

8
papers

1,297
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

1792
citing authors

#	ARTICLE	IF	CITATIONS
1	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1838-1847.	27.0	1,010
2	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. <i>Circulation</i> , 2020, 142, 1996-1998.	1.6	81
3	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019, 218, 46-56.	2.7	72
4	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2571-2573.	5.3	44
5	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. <i>PLoS ONE</i> , 2020, 15, e0237665.	2.5	29
6	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 78, 859-866.	2.8	27
7	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. <i>Atherosclerosis</i> , 2021, 334, 93-100.	0.8	25
8	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. <i>Circulation</i> , 2022, 145, 626-628.	1.6	9